NUVB
Nuvation Bio Inc - Ordinary Shares - Class A

2,670
Mkt Cap
$1.77B
Volume
33,808.00
52W High
$5.55
52W Low
$1.54
PE Ratio
-8.24
NUVB Fundamentals
Price
$5.17
Prev Close
$5.22
Open
$5.34
50D MA
$3.68
Beta
1.44
Avg. Volume
8.3M
EPS (Annual)
-$2.11
P/B
4.68
Rev/Employee
$35,786.36
Loading...
Loading...
News
all
press releases
Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of +5.88% and +95.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12h ago
News Placeholder
More News
News Placeholder
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the third quarter ended...
Business Wire·14h ago
News Placeholder
Nuvation Bio to Participate in Upcoming Investor Conferences
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief...
Business Wire·5d ago
News Placeholder
MiMedx (MDXG) Tops Q3 Earnings and Revenue Estimates
MiMedx (MDXG) delivered earnings and revenue surprises of +114.29% and +19.99%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203...
Business Wire·12d ago
News Placeholder
Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks·2mo ago
News Placeholder
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +93.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +14.29% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy
Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·4mo ago
News Placeholder
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief...
Business Wire·8mo ago

Latest NUVB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.